{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:12:57Z","timestamp":1790086377734,"version":"4.0.1"},"reference-count":28,"publisher":"American Academy of Pediatrics (AAP)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND:<\/jats:title>\n                  <jats:p>On March 22, 2002, Internet-based reports (IBRs) were added to the Vaccine Adverse Event Reporting System (VAERS) to allow rapid, expedited reporting of adverse events (AEs) in anticipation of wider use of counter-bioterrorism vaccines such as those against smallpox and anthrax.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>OBJECTIVES:<\/jats:title>\n                  <jats:p>To evaluate the impact of IBRs on the timeliness and completeness of vaccine AE reporting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>To evaluate timeliness and completeness, we compared the proportions of IBRs with non\u2013Internet-based reports (NIBRs). Report interval was analyzed for timeliness and age at vaccination, birth date, and onset date for report completeness. To evaluate the impact of the smallpox vaccination program, we compared smallpox vaccine reports separately. Because influenza vaccine is the most widely used vaccine in adults each year, we compared influenza vaccine reports separately.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>During the study period, VAERS received 54 364 NIBRs (85.8%) and 9008 IBRs (14.2%). Sixteen percent (1455) of IBRs followed smallpox vaccination. Overall, for all vaccines and for smallpox vaccine alone, IBRs had a greater proportion of completeness and a shorter report interval. The proportion of most frequently reported AEs did not differ between IBRs and NIBRs. A higher proportion of adults (18\u201364 years old) who received influenza vaccine chose to complete an IBR (62% vs 48%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>The improved timeliness and completeness of IBRs allow VAERS to more rapidly detect new or rare vaccine AEs. This important advantage is critical in times of increased public concern about vaccine safety. Clinical vaccine providers should be aware of VAERS and use IBRs whenever feasible to report vaccine AEs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2010-1722g","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T03:31:46Z","timestamp":1303183906000},"page":"S39-S44","source":"Crossref","is-referenced-by-count":18,"title":["Internet-Based Reporting to the Vaccine Adverse Event Reporting System: A More Timely and Complete Way for Providers to Support Vaccine Safety"],"prefix":"10.1542","volume":"127","author":[{"given":"Penina","family":"Haber","sequence":"first","affiliation":[{"name":"Immunization Safety Office, Division of Healthcare Quality Promotion, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Iskander","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Division of Healthcare Quality Promotion, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimp","family":"Walton","sequence":"additional","affiliation":[{"name":"Office of Information Science and Technology, Office of the Director, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Division of Healthcare Quality Promotion, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin S.","family":"Kohl","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Division of Healthcare Quality Promotion, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2011,5,1]]},"reference":[{"key":"2021120900252132800_B1"},{"issue":"1","key":"2021120900252132800_B2","first-page":"1","article-title":"Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)\u2014United States, 1991\u20132001 [published correction appears in MMWR Morb Mortal Wkly Rep. 2003;52(06):113]","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"key":"2021120900252132800_B3","unstructured":"Centers for Disease Control and Prevention. US Food and Drug Administration. Table of reportable events following vaccination. Available at: vaers.hhs.gov\/resources\/VAERS_Table_of_Reportable_Events_Following_Vaccination.pdf. Accessed January, 2010"},{"issue":"6","key":"2021120900252132800_B4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The Vaccine Adverse Event Reporting System (VAERS)","volume":"12","author":"Chen","year":"1994","journal-title":"Vaccine"},{"issue":"4","key":"2021120900252132800_B5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the Vaccine Adverse Event Reporting System","volume":"23","author":"Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"2021120900252132800_B6","unstructured":"US Food and Drug Administration. 21 CFR part 600.80. Postmarketing reporting of adverse experiences. Fed Regist. 1997;62:52252\u201352253. Available at: www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=314.80. Accessed January, 2010"},{"issue":"1","key":"2021120900252132800_B7","first-page":"10","article-title":"The complicated task of monitoring vaccine safety","volume":"112","author":"Ellenberg","year":"1997","journal-title":"Public Health Rep"},{"issue":"4","key":"2021120900252132800_B8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0022-3476(97)70056-8","article-title":"Descriptive epidemiology of adverse events after immunization: reports to the Vaccine Adverse Event Reporting System (VAERS) 1991\u20131994","volume":"131","author":"Braun","year":"1997","journal-title":"J Pediatr"},{"issue":"22","key":"2021120900252132800_B9","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1016\/S0264-410X(99)00132-2","article-title":"An overview of the Vaccine Adverse Event Reporting System (VAERS) as a surveillance system","volume":"17","author":"Singleton","year":"1999","journal-title":"Vaccine"},{"issue":"7","key":"2021120900252132800_B10","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"key":"2021120900252132800_B11","unstructured":"Centers for Disease Control and Prevention. VAERS form. Available at: www.vaers.hhs.gov\/resources\/vaers_form.pdf. Accessed January, 2010"},{"issue":"9","key":"2021120900252132800_B12","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3928\/0090-4481-20040901-11","article-title":"The role of the Vaccine Adverse Event Reporting System (VAERS) in monitoring vaccine safety","volume":"33","author":"Iskander","year":"2004","journal-title":"Pediatr Ann"},{"key":"2021120900252132800_B13","volume-title":"COSTART: Coding Symbol for Thesaurus of Adverse Reaction Terms","author":"US Food and Drug Administration","year":"1989","edition":"5th ed."},{"issue":"5","key":"2021120900252132800_B14","first-page":"88","article-title":"Notice to readers: smallpox vaccine adverse events monitoring and response system for the first stage of the smallpox vaccination program","volume":"52","author":"Centers for Disease Control and Prevention","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"2021120900252132800_B15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/bsp.2005.3.198","article-title":"Use of an electronic monitoring system for self-reporting smallpox vaccine reactions","volume":"3","author":"Olmsted","year":"2005","journal-title":"Biosecur Bioterror"},{"issue":"27","key":"2021120900252132800_B16","first-page":"577","article-title":"Intussusception among recipients of rotavirus vaccine: United States, 1998\u20131999","volume":"48","author":"Centers for Disease Control and Prevention","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"2021120900252132800_B17","doi-asserted-by":"crossref","DOI":"10.1542\/peds.107.6.e97","article-title":"Intussusception among recipients of rotavirus vaccine: reports to the Vaccine Adverse Event Reporting System","volume":"107","author":"Zanardi","year":"2001","journal-title":"Pediatrics"},{"issue":"4","key":"2021120900252132800_B18","doi-asserted-by":"crossref","DOI":"10.1542\/peds.113.4.e353","article-title":"An analysis of rotavirus vaccine reports to the Vaccine Adverse Event Reporting System: more than intussusception alone?","volume":"113","author":"Haber","year":"2004","journal-title":"Pediatrics"},{"issue":"40","key":"2021120900252132800_B19","first-page":"1023","article-title":"Guillain-Barr\u00e9 syndrome among recipients of Menactra meningococcal conjugate vaccine: United States, June\u2013July 2005","volume":"54","author":"Centers for Disease Control and Prevention","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"2021120900252132800_B20","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/aje\/kwh269","article-title":"Myopericarditis following smallpox vaccination","volume":"160","author":"Arness","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"21","key":"2021120900252132800_B21","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1001\/jama.294.21.2734","article-title":"Adverse events associated with smallpox vaccination in the United States, January\u2013October 2003","volume":"294","author":"Casey","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"2021120900252132800_B22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0749-3797(01)00430-5","article-title":"Pediatric deaths reported after vaccination: the utility of information obtained from parents","volume":"22","author":"Silvers","year":"2002","journal-title":"Am J Prev Med"},{"issue":"4","key":"2021120900252132800_B23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1471-1842.2002.00402.x","article-title":"Doctors' and patients' use of the Internet for healthcare: a study from one general practice","volume":"19","author":"Rose","year":"2002","journal-title":"Health Info Libr J"},{"key":"2021120900252132800_B24","unstructured":"Manhattan Research. Taking the pulse v5.0. Available at: www.manhattanresearch.com\/products\/Strategic_Advisory\/ttp\/default.aspx. Accessed January, 2010"},{"key":"2021120900252132800_B25","unstructured":"International Conference on Harmonisation (ICH). Available at: www.ich.org\/home.html. Accessed January, 2010"},{"key":"2021120900252132800_B26","unstructured":"US Food and Drug Administration. Guidance for industry E2B(M): Data elements for transmission of individual case safety reports. Available at: www.fda.gov\/downloads\/RegulatoryInformation\/Guidances\/ucm129434.pdf. Accessed January, 2010"},{"issue":"20","key":"2021120900252132800_B27","first-page":"431","article-title":"Immunization registry progress: United States, January\u2013December 2002","volume":"53","author":"Centers for Disease Control and Prevention","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"2021120900252132800_B28","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1542\/peds.2007-3793","article-title":"Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007","volume":"121","author":"Haber","year":"2008","journal-title":"Pediatrics"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/127\/Supplement_1\/S39\/824244\/zpe10511000s39.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/127\/Supplement_1\/S39\/824244\/zpe10511000s39.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T06:10:37Z","timestamp":1639030237000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/127\/Supplement_1\/S39\/30120\/Internet-Based-Reporting-to-the-Vaccine-Adverse"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,1]]},"references-count":28,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2011,5,1]]},"published-print":{"date-parts":[[2011,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2010-1722g","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,1]]}}}